Company profile for Sigilon Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of acute and chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to restore functions or provide therapeutic molecules needed by patients living with acute or chronic diseases such as diabetes and...
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of acute and chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to restore functions or provide therapeutic molecules needed by patients living with acute or chronic diseases such as diabetes and lysosomal diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
100 Binney St, STE 600, STE 2C, Cambridge, MA 02142
Telephone
Telephone
+1 6173367540
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-sigilon-therapeutics-301899110.html

PR NEWSWIRE
14 Aug 2023
Lilly’s yes-no-yes journey to acquiring Sigilon
Lilly’s yes-no-yes journey to acquiring Sigilon

13 Jul 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/he-wanted-deal-lilly-wanted-partnership-could-sigilon-make-it-anymore-obvious

Annalee Armstrong FIERCE BIOTECH
13 Jul 2023
Lilly buys diabetes cell therapy partner Sigilon for $35M
Lilly buys diabetes cell therapy partner Sigilon for $35M

30 Jun 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/lilly-raiding-biotech-bargain-bin-buys-diabetes-cell-therapy-partner-sigilon-35m

Nick Paul Taylor FIERCE BIOTECH
30 Jun 2023

https://www.contractpharma.com/contents/view_breaking-news/2023-06-29/lilly-to-acquire-diabetes-cell-therapy-company-sigilon-therapeutics/

CONTRACT PHARMA
29 Jun 2023

https://www.globenewswire.com/news-release/2023/05/22/2673250/0/en/Sigilon-Announces-Reverse-Stock-Split-of-Common-Stock.html

GLOBENEWSWIRE
22 May 2023

https://www.globenewswire.com/news-release/2023/05/09/2664297/0/en/Sigilon-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Business-Highlights.html

GLOBENEWSWIRE
09 May 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty